Bristol-Myers Squibb
BMS’ Opdivo+Yervoy+Chemo combo shows superior overall survival in first-line lung cancer
October 23, 2019Research and Development Bristol-Myers Squibb, Cancer, NSCLC, Yervoy, lung cancer, opdivo, pharma
Bristol Myers Squibb has lifted the curtain on new Phase 3 data for its blockbuster immunotherapy Opdivo (nivolumab), showing that …
BMS’ Opdivo bests chemotherapy in oesophageal squamous cell carcinoma
October 2, 2019Research and Development Bristol-Myers Squibb, Cancer, ESMO 2019, opdivo, pharma
Bristol-Myers Squibb took the opportunity at the European Society for Medical Oncology (ESMO) 2019 Annual Congress to present new Phase …
EMA’s CHMP recommends new dosing schedule for Opdivo in melanoma
September 25, 2019Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, CHMP, EMA, melanoma, opdivo, pharma
Bristol-Myers Squibb has revealed that its blockbuster immunotherapy drug Opdivo (nivolumab) has secured recommendation from the EMA’s Committee for Medicinal …
BMS unveils strong five-year efficacy data for Opdivo in lung cancer
September 11, 2019Research and Development Bristol-Myers Squibb, Cancer, immunotherapy, lung cancer, pharma
Bristol-Myers Squibb has unveiled pooled five-year efficacy and safety results for its blockbuster immunotherapy Opdivo (nivolumab) drawn from two Phase …
BMS’ blockbuster Opdivo flies high and falls short in non-small cell lung cancer
July 25, 2019Research and Development Bristol-Myers Squibb, NSCLC, immuntherapy, lung cancer, opdivo, pharma
Bristol-Myers Squibb has pulled back the veil on new data from two analyses of its blockbuster immunotherapy Opdivo (nivolumab) in …
Top Ten most popular articles on Pharmafile.com this week
June 28, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Allergan, Bristol-Myers Squibb, China, GSK, Novartis, Takeda, brexit
This week was diverse as always in terms of news coming out of the pharma industry, but the biggest news …
Bristol-Myers Squibb to sell off Celgene’s Otezla ahead of $74 billion merger
June 24, 2019Manufacturing and Production Bristol-Myers Squibb, Celgene, FTC, otezla, pharma, psoriasis
Bristol-Myers Squibb has agreed to sell off Celgene’s psoriasis treatment Otezla, to appease antitrust regulators. BMS will divest one of …
Catalent to purchase Italy manufacturing facility from BMS
June 20, 2019Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, Cataletnt, pharma
Bristol-Myers Squibb has reached an agreement with Catalent for the latter to acquire its Anagni, Italy-based facility which specialises in …
Long term BMS exec Johanna Mercier joins Gilead as new Chief Commercial Officer
May 30, 2019Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Gilead, cco, commercial, pharma
Gilead Sciences have said Bristol-Myers Squibb exec Johanna Mercier will be the firm’s new Chief Commercial Officer. In her new …
BMS blockbuster Opdivo falls short at Phase 3 in MGMT-unmethylated glioblastoma multiforme
May 10, 2019Medical Communications, Research and Development BMS, Bristol-Myers Squibb, glioblastoma multiforme, pharma, trial failure
Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) has hit a hurdle, failing its primary endpoint in a Phase 3 trial investigating …
Disapproval from top shareholder throws $74bn BMS/Celgene merger into doubt
February 28, 2019Sales and Marketing Bristol-Myers Squibb, Celgene, acquisition, pharma
The news kicked off 2009 with a bang when Bristol-Myers Squibb announced it intended to acquire Celgene for $74 billion, …
Top Ten most popular articles on Pharmafile.com this week!
January 11, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Bristol-Myers Squibb, Shire, Takeda, bristol myers squibb, death row, pharma, top 10
With the completion of Takeda’s £46 billion acquisition of Shire finally done, another even bigger merger was announced as US …
BMS to acquire Celgene for $74 billion in biggest-ever pharma deal
January 4, 2019Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, acquisition, pharma
Starting off 2019 with a bang, Bristol-Myers Squibb has announced its intention to acquire fellow drugmaker Celgene as part of …
CHMP approve Bristol-Myers Squibb’s Sprycel for paediatric patients with Ph+ ALL
December 17, 2018Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Sprycel, all
New Jersey-based firm Bristol -Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the …
Opdivo to be made available to UK melanoma patients via the Cancer Drugs Fund
November 30, 2018Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, NICE, UK, melanoma, pharma
Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) is set to be made available to patients in the UK via the Cancer …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
